問卷

TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of General Internal Medicine

Division of Rheumatology

Division of Dermatology

Taipei Veterans General Hospital (在職)

Division of General Internal Medicine

更新時間:2024-06-13

黃文男HUANG, WEN-NAN
  • Principal Investigator
  • Clinical Trial Experience (year)
  • yij1219@vghtc.gov.tw

篩選

List

53Cases

2024-11-01 - 2029-12-11

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2025-11-15 - 2030-03-31

Phase I

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting3Sites

2020-07-13 - 2024-04-30

Phase II

Completed
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
  • Condition/Disease

    Systemic Lupus Erythematosus

  • Test Drug

    LY3471851

Participate Sites
4Sites

Recruiting4Sites

2025-10-28 - 2027-04-16

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2020-12-01 - 2025-12-31

Phase IV

Active
Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis: a 12 Month, Single-arm, Observational Study in Taiwan Population
  • Condition/Disease

    Lupus Nephritis

  • Test Drug

    Myfortic 180 mg、360 mg Gastro-Resistant Tablets

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2009-09-30 - 2010-08-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2023-01-23 - 2027-04-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2024-12-02 - 2030-12-09

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2022-03-01 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-01-15 - 2031-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites